Antagonizing ClpP: A New Power Play in Targeted Therapy for AML.

Karilyn Larkin, John C Byrd

Abstract readComment

In one paragraph

Article in Cancer cell, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it

0cells of the map it votes in

5citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

Targeting mitochondrial ClpP: structural insights and therapeutic potential of ClpP agonists in cancer therapy.Oncology reviews · 2025
Review
The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways.Cell communication and signaling : CCS · 2023
Review
The Capacity of Long-Term in Vitro Proliferation of Acute Myeloid Leukemia Cells Supported Only by Exogenous Cytokines Is Associated with a Patient Subset with Adverse Outcome.Cancers · 2019
Article
Detecting subnetwork-level dynamic correlations.Bioinformatics (Oxford, England) · 2017
Article
Cell intrinsic and extrinsic regulation of leukemia cell metabolism.International journal of hematology · 2016
Review

4 · The record

Corrections and comments

Comment on
Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia.2015

5 · Who and what money

Authors and funding

2 authors.

Karilyn LarkinDivision of Hematology, Department of Medicine, The Ohio State University, Columbus, OH 43210, USA.

John C ByrdDivision of Hematology, Department of Medicine, The Ohio State University, Columbus, OH 43210, USA; Comprehensive Cancer Center, The Ohio State University, B302 Starling-Loving Hall, 320 West 10(th) Avenue, Columbus, OH 43210, USA. Electronic address: john.byrd@osumc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this issue of Cancer Cell, Cole and colleagues report a non-mutant mitochondrial protein (ClpP) that is overexpressed in a wide range of acute myeloid leukemia (AML) cases, but not in normal hematopoietic precursors. This finding suggests a potentially unique therapeutic targeting opportunity for this difficult-to-treat disease.

Indexed as

AnimalsEndopeptidase ClpEnzyme InhibitorsHumansLeukemia, Myeloid, AcuteMaleEndopeptidase ClpEnzyme Inhibitors

Identifiers

PMID26058072

DOI10.1016/j.ccell.2015.05.013

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.